Nuna Araújo, Carla S B Viegas, Eva Zubía, Joana Magalhães, Acácio Ramos, Maria M Carvalho, Henrique Cruz, João Paulo Sousa, Francisco J Blanco, Cees Vermeer and 1 more
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 3 countries.
Nuna AraújoCentre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal.
Carla S B ViegasCentre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal.
Eva ZubíaDepartment of Organic Chemistry, Faculty of Marine and Environmental Sciences, University of Cadiz, 11510 Puerto Real (Cádiz), Spain.
Joana MagalhãesUnidad de Medicina Regenerativa, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, Spain.ORCID 0000-0002-1395-2209
Acácio RamosDepartment of Orthopedics and Traumatology, Hospital Particular do Algarve (HPA), 8005-226 Gambelas-Faro, Portugal.
Maria M CarvalhoDepartment of Orthopedics and Traumatology, Hospital Particular do Algarve (HPA), 8005-226 Gambelas-Faro, Portugal.
Henrique CruzDepartment of Orthopedics and Traumatology, Hospital Particular do Algarve (HPA), 8005-226 Gambelas-Faro, Portugal.
João Paulo SousaDepartment of Orthopedics and Traumatology, Hospital Particular do Algarve (HPA), 8005-226 Gambelas-Faro, Portugal.
Francisco J BlancoUnidad de Medicina Regenerativa, Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, Spain.ORCID 0000-0001-9821-7635
Cees VermeerCardiovascular Research Institute CARIM, Maastricht University, 6229 EV Maastricht, The Netherlands.
Dina C SimesCentre of Marine Sciences (CCMAR), University of Algarve, 8005-139 Faro, Portugal.ORCID 0000-0002-5145-4753
University of Algarve · PTUniversidade da Coruña · ESMaastricht University · NLUniversidad de Cádiz · ES
Funding
Fundação para a Ciência e Tecnologia (FCT) fellowship SFRH/BD/111824/2015Fundação para a Ciência e Tecnologia (FCT) project UIDB/04326/2020Fundação para a Ciência e Tecnologia (FCT) transitional provision DL57/2016/CP1361/CT0006
6 · The paper itself
Abstract
Osteoarthritis (OA) remains a prevalent chronic disease without effective prevention and treatment. Amentadione (YP), a meroditerpenoid purified from the alga
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Amentadione from the Alga · full record | OpenQuestion